
Isabelle Quadrio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/893802/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
2	Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiology of Aging, 2012, 33, 1009.e11-1009.e19.	1.5	108
3	Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. Acta Neuropathologica, 2011, 121, 39-57.	3.9	105
4	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. Journal of Alzheimer's Disease, 2012, 31, 13-20.	1.2	94
5	Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Research, 2010, 1357, 175-183.	1.1	69
6	Change of the dependent variable. Neurobiology of Aging, 2013, 34, e1.	1.5	69
7	Association of Cerebrospinal Fluid Prion Protein Levels and the Distinction Between Alzheimer Disease and Creutzfeldt-Jakob Disease. JAMA Neurology, 2015, 72, 267.	4.5	69
8	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. Clinica Chimica Acta, 2015, 449, 9-15.	0.5	66
9	Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2011, 26, 553-563.	1.2	65
10	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
11	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. Journal of Neurology, 2019, 266, 195-206.	1.8	58
12	CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro-Oncology, 2015, 17, 1497-1503.	0.6	52
13	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. Clinical Chemistry, 2012, 58, 787-789.	1.5	50
14	Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease. Frontiers in Neurology, 2015, 6, 247.	1.1	49
15	TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration. Cerebellum, 2019, 18, 245-254.	1.4	44
16	Oral Transmission of L-type Bovine Spongiform Encephalopathy in Primate Model. Emerging Infectious Diseases, 2012, 18, 142-145.	2.0	38
17	Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers. Frontiers in Neurology, 2015, 6, 153.	1.1	38
18	Isotopic Evidence for Disrupted Copper Metabolism in Amyotrophic Lateral Sclerosis. IScience, 2018, 6, 264-271.	1.9	37

ISABELLE QUADRIO

#	Article	IF	CITATIONS
19	Emergence of two prion subtypes in ovine PrP transgenic mice infected with human MM2-cortical Creutzfeldt-Jakob disease prions. Acta Neuropathologica Communications, 2016, 4, 10.	2.4	31
20	Absence of Evidence for a Causal Link between Bovine Spongiform Encephalopathy Strain Variant L-BSE and Known Forms of Sporadic Creutzfeldt-Jakob Disease in Human PrP Transgenic Mice. Journal of Virology, 2016, 90, 10867-10874.	1.5	26
21	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
22	Pathologic Prion Protein Spreading in the Peripheral Nervous System of a Patient With Sporadic Creutzfeldt-Jakob Disease. Archives of Neurology, 2004, 61, 747.	4.9	17
23	A combination of total tau and neurofilaments discriminates between neurodegenerative and primary psychiatric disorders. European Journal of Neurology, 2020, 27, 1164-1169.	1.7	16
24	Analytical validation of microdialysis analyzer for monitoring glucose, lactate and pyruvate in cerebral microdialysates. Clinica Chimica Acta, 2011, 412, 647-654.	0.5	15
25	Rapid screening and confirmatory methods for biochemical diagnosis of human prion disease. Journal of Virological Methods, 2011, 175, 216-223.	1.0	13
26	Molecular diagnosis of human prion disease. Expert Opinion on Medical Diagnostics, 2011, 5, 291-306.	1.6	12
27	Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 2-11.	0.5	11
28	Amyloid-Beta Radiotracer [18F]BF-227 Does Not Bind to Cytoplasmic Glial Inclusions of Postmortem Multiple System Atrophy Brain Tissue. Contrast Media and Molecular Imaging, 2018, 2018, 1-7.	0.4	11
29	Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis. Journal of Neurology, 2022, 269, 377-388.	1.8	10
30	Are the Interactions between Recombinant Prion Proteins and Polymeric Surfaces Related to the Hydrophilic/Hydrophobic Balance?. Macromolecular Bioscience, 2012, 12, 830-839.	2.1	9
31	Prion potentiation after life-long dormancy in mice devoid of PrP. Brain Communications, 2021, 3, fcab092.	1.5	9
32	The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. Journal of Neural Transmission, 2015, 122, 975-991.	1.4	8
33	Development of an automated capillary nano-immunoassay—Simple Western assay—to quantify total TDP43 protein in human platelet samples. Analytical and Bioanalytical Chemistry, 2019, 411, 267-275.	1.9	8
34	Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues. Laboratory Investigation, 2009, 89, 406-413.	1.7	7
35	Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD–ALS spectrum. Journal of Neurology, 2022, 269, 1522-1529.	1.8	7
36	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7

ISABELLE QUADRIO

#	Article	IF	CITATIONS
37	Predictive testing for Huntington disease over 24 years: Evolution of the profile of the participants and analysis of symptoms. Molecular Genetics & Genomic Medicine, 2019, 7, e00881.	0.6	6
38	The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?. Clinical Biochemistry, 2019, 72, 15-23.	0.8	4
39	An automated alert system based on the p-Tau/Tau ratio to quickly inform health professionals upon a suspected case of sporadic Creutzfeldt-Jakob disease Journal of the Neurological Sciences, 2020, 415, 116971.	0.3	4
40	Proteinopathies associated to repeat expansion disorders. Journal of Neural Transmission, 2022, 129, 173.	1.4	4
41	Interdisciplinary Case Study: Geochemistry Meets the Clinic in Search for a Metal ALS Biomarker. IScience, 2019, 11, 531-535.	1.9	2
42	Nonâ€Adhesive Behavior of New Nanostructured PNIPAM Surfaces Towards Specific Neurodegenerative Proteins: Application to Storage and Titration of Tau Proteins. Macromolecular Bioscience, 2012, 12, 1354-1363.	2.1	1
43	Increasing the Detection Limit of the Parkinson Disorder through a Specific Surface Chemistry Applied onto Inner Surface of the Titration Well. Journal of Functional Biomaterials, 2012, 3, 298-312.	1.8	1
44	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1
45	Charge detection mass spectrometry on human-amplified fibrils from different synucleinopathies. Chemical Communications, 2022, 58, 7192-7195.	2.2	1
46	Alzheimer's Diseases: Towards Biomarkers for an Early Diagnosis. , 2011, , .		0
47	A New Approach for Detection Improvement of the Creutzfeldt-Jakob Disorder through a Specific Surface Chemistry Applied onto Titration Well. Biosensors, 2012, 2, 433-447.	2.3	0
48	C9orf72 Protein Plasmatic Concentrations Are Similar between C9ORF72 Expansion Carriers and Noncarriers in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 46, 180-185.	0.7	0
49	Marqueurs biologiques et maladie d'Alzheimer. Revue Francophone Des Laboratoires, 2021, 2021, 18-27.	0.0	0